Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
View original at globenewswire.comArtelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
2020 ASCO guidelines recommend no specific pharmacological intervention as standard of care for cancer anorexia cachexia
60% confidenceThere is no FDA-approved pharmacological treatment for cancer anorexia cachexia
60% confidenceFollowing positive Phase 2 results and coverage by UK and USA media outlets, Artelo has received multiple expressions of potential collaboration interest from global and regional pharmaceutical companies
60% confidenceThe collaboration with Queen's University Belfast and partners broadens ART27.13's therapeutic profile beyond cancer-related anorexia while preserving internal focus on the lead indication
60% confidenceART12.11 showed antidepressant-like activity on par with sertraline with improved cognitive benefits in preclinical models
60% confidenceART26.12 showed sustained analgesic effects without development of tolerance in osteoarthritis pain model, matching naproxen in efficacy
60% confidenceArtelo is not a one-trick biotech but a platform play in one of medicine's most underserved mechanistic categories
60% confidenceART27.13's 6.4% weight gain versus 5.4% weight loss in placebo represents a clinically meaningful signal in cancer anorexia cachexia
60% confidence
Cited in these Via News reports
- AI-Designed Antibody BD200 Outperforms Standard Treatments in Drug-Resistant Cancers, Marking First Clinical Trial for Machine Learning Platform →
- Amgen Merges R&D and AI Leadership as Global Pharma Embeds Generative AI Into Research Strategy →
- China's Kelun-Biotech Fields 30+ Oncology Candidates in Global ADC Race Against Pfizer, Regeneron →
- Global ADC Combination Race Peaks in 2026–2027, Compressing Binary Risk Across Three Continents →
- Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals →
- Vepdegestrant's 5-Month PFS Anchors Cross-Border Oncology Deals as 2026 PDUFA Cluster Reshapes Global Drug Valuations →